Skip Navigation

Cardiovascular Research 1999 44(1):17-19; doi:10.1016/S0008-6363(99)00215-1
© 1999 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Oemar, B. S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oemar, B. S
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1999, European Society of Cardiology

Is interleukin-1 beta a triggering factor for restenosis?

Barry S Oemar*

CuraGen Coorporation, 555 Long Wharf Drive, New Haven, CT 06511, USA

* Tel.: +1-203-401-3330, ext. 325; fax: +1-203-401-3337 boemar@curagen.com

Received 1 July 1999; accepted 1 July 1999

The first 10% of the full text of this article appears below.

See article by Chamberlain et al. [9] (pages 156–165) in this issue.

Today, more than 20 years after percutaneous transluminal coronary angioplasty (PTCA) was introduced into the clinic by Andreas Grüntzig [1], PTCA has become a well-established and routine procedure for myocardial revascularization of patients with coronary heart disease (CHD). However, restenosis occurs in these patients at a rate between 30 and 50%, despite a successful initial procedure (for an extensive reviews see Refs. [2–5]). More than 60 large-scale clinical trials later, we are still struggling to understand why restenosis occurs in some but not in others, and why after 20 years the rate of restenosis is virtually unchanged, despite the availability of modern therapeutics and extensive knowledge in vascular biology [6–8]. The paper presented . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?